| Literature DB >> 15993809 |
Miles Congreve1, Christopher W Murray, Tom L Blundell.
Abstract
It has long been recognized that knowledge of the 3D structures of proteins has the potential to accelerate drug discovery, but recent developments in genome sequencing, robotics and bioinformatics have radically transformed the opportunities. Many new protein targets have been identified from genome analyses and studied by X-ray analysis or NMR spectroscopy. Structural biology has been instrumental in directing not only lead optimization and target identification, where it has well-established roles, but also lead discovery, now that high-throughput methods of structure determination can provide powerful approaches to screening.Mesh:
Year: 2005 PMID: 15993809 DOI: 10.1016/S1359-6446(05)03484-7
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851